TRPV1 Modulator Compounds for Pain and Inflammatory Conditions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pain, urinary incontinence, ulcers, inflammatory bowel disease, and irritable bowel syndrome are inadequate in terms of efficacy and are associated with significant side effects, highlighting a need for new therapeutic options that can effectively manage these conditions with improved safety and bioavailability.
Innovation Solution
Development of novel compounds, specifically those of Formulas I-V, which are potent at Vanilloid Receptor 1 (TRPV1) and exhibit improved solubility and pharmacokinetics, potentially reducing side effects and enhancing bioavailability, formulated into compositions for administration to treat or prevent pain, urinary incontinence, ulcers, inflammatory bowel disease, and irritable bowel syndrome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing commercial drug treatments for UI are used, then some symptom relief may be achieved, but complete success is not achieved in all classes of UI patients and significant adverse side effects occur
Solution Approach 1:
The patent applies parameter changes by developing new chemical compounds with modified molecular structures (Formulas I-V) that alter the pharmacological parameters of TRPV1 receptor interaction. This results in improved treatment efficacy across different UI patient classes while reducing adverse side effects through optimized compound selectivity and potency.
Solution Approach 2:
The patent employs composite materials by creating complex multi-substituted heterocyclic compounds that combine multiple functional groups and structural elements. These composite molecular structures enable simultaneous optimization of receptor binding affinity, solubility, and pharmacokinetic properties, achieving both high efficacy and reduced side effects.
2Reliability
If existing pain treatments are used, then pain management is provided, but the treatments are inadequate in terms of efficacy and are associated with significant side effects
Solution Approach 1:
The patent implements parameter changes by synthesizing novel TRPV1 modulators with optimized molecular parameters including substituent patterns, ring structures, and functional groups. These parameter optimizations enhance pain management efficacy while minimizing side effects through improved receptor selectivity and reduced off-target activity.
Solution Approach 2:
The patent uses intermediary compounds as mediators between the TRPV1 receptor and the therapeutic effect. The novel compounds of Formulas I-V act as intermediary molecules that specifically modulate TRPV1 channel activity, providing effective pain management while avoiding the side effects associated with traditional analgesics that act through different mechanisms.
3Quantity of substance
If novel compounds of Formulas I-V are developed, then enhanced solubility and bioavailability are achieved, but this requires complex chemical synthesis and structural optimization
Solution Approach 1:
The patent applies parameter changes by systematically modifying molecular parameters such as substituent types, ring configurations, and functional group positions in the compounds of Formulas I-V. These parameter changes optimize the balance between solubility, bioavailability, and synthetic feasibility, achieving enhanced drug properties without excessive synthesis complexity.
Solution Approach 2:
The patent implements local quality by making specific localized modifications to particular regions of the molecular structure (such as substituting specific hydrogen atoms with functional groups at defined positions). This approach allows optimization of solubility and bioavailability at specific molecular locations without requiring complete redesign of the entire molecular structure, thereby reducing overall synthesis complexity.
Data Source
AI summary
A compound of Formula: (I) or a pharmaceutically acceptable derivative thereof, where Ar1, Ar2, X, R3, and m are as disclosed herein. Compounds of Formulae (I)-(V) and pharmaceutically acceptable derivatives thereof; compositions comprising an effective amount of a compound of Formulae (I)-(V) or a pharmaceutically acceptable derivative thereof; and methods for treating or preventing pain, UI, an ulcer, IBD, or IBS in an animal comprising administering to an animal in need thereof an effective amount of a compound of Formulae (I)-(V) or a pharmaceutically acceptable derivative thereof are disclosed herein.